Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

Image: Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody that targets residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease. Photo: courtesy of hywards / FreeDigitalPhotos.net.